62 related articles for article (PubMed ID: 3522158)
1. Evaluation of a stable 5-F prostacyclin analogue as an antithrombotic agent in haemodialysis.
Nicholson NS; Smith SL; Taite BB; Krueger A; Fuller GC
Drugs Exp Clin Res; 1986; 12(5):371-5. PubMed ID: 3522158
[TBL] [Abstract][Full Text] [Related]
2. Effect of a stable prostacyclin analogue on platelet function and experimentally-induced thrombosis in the microcirculation.
Sim AK; McCraw AP; Cleland ME; Nishio S; Umetsu T
Arzneimittelforschung; 1985; 35(12):1816-8. PubMed ID: 3913423
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of the antithrombotic effect of prostacyclin by simultaneous administration of aminophylline in a canine model of coronary artery thrombosis.
Romson JL; Hook BG; Lucchesi BR
J Pharmacol Exp Ther; 1983 Nov; 227(2):288-94. PubMed ID: 6313894
[TBL] [Abstract][Full Text] [Related]
4. Prevention of coagulation during hemodialysis by a combination of the stable prostacyclin analogue CG 4203 and low-dose heparin.
Maurin N; Ballmann M
Clin Nephrol; 1988 Jul; 30(1):35-41. PubMed ID: 3061692
[TBL] [Abstract][Full Text] [Related]
5. Delayed antiischemic effect of prostaglandin I2 and of a new stable prostaglandin I2 analogue, 7-oxo-prostacyclin-Na, in experimental model angina in dogs.
Szekeres L; Krassói I; Pataricza J; Udvary E
Adv Myocardiol; 1985; 6():607-18. PubMed ID: 3887531
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of prostaglandin D2 (PGD2) as an anticoagulative agent for haemodialysis in comparison with prostaglandin E1 (PGE1).
Nakagawa S; Matsui N; Akiba T; Shinoda T; Fukudome Y; Ozawa K; Baba M; Nakanishi T; Takeuchi J
Proc Eur Dial Transplant Assoc; 1981; 18():117-21. PubMed ID: 7036145
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological properties of the new stable prostacyclin analogue 3-Oxa-methano-prostaglandin I.
Yamamoto T; Satoh K; Nishimura T; Horikawa N; Mine T; Hirohashi T; Hara Y
Arzneimittelforschung; 1994 Apr; 44(4):483-90. PubMed ID: 8011001
[TBL] [Abstract][Full Text] [Related]
8. The effects of prostacyclin (PGI2) on endotoxin shock and endotoxin-induced platelet aggregation in dogs.
Fletcher JR; Ramwell PW
Circ Shock; 1980; 7(3):299-308. PubMed ID: 7004660
[TBL] [Abstract][Full Text] [Related]
9. Prostacyclin (epoprostenol) as the sole antithrombotic agent in postdilutional hemofiltration.
Canaud B; Mion C; Arujo A; N'Guyen QV; Paleyrac G; Hemmendinger S; Cazenave JP
Nephron; 1988; 48(3):206-12. PubMed ID: 2965311
[TBL] [Abstract][Full Text] [Related]
10. The cardiovascular and platelet actions of 9 beta-methyl carbacyclin (ciprostene), a chemically stable analogue of prostacyclin, in the dog and monkey.
Allan G; Follenfant MJ; Lidbury P; Oliver PL; Whittle BJ
Br J Pharmacol; 1985 Jun; 85(2):547-55. PubMed ID: 3896365
[TBL] [Abstract][Full Text] [Related]
11. Effects of PGI2, CH-7284 and CH-7384 on spontaneous platelet aggregation and blood pressure of anaesthetized beagles.
Hermán F; Malomvölgyi B; Hadházy P; Magyar K
Biomed Biochim Acta; 1988; 47(10-11):S113-6. PubMed ID: 3073758
[TBL] [Abstract][Full Text] [Related]
12. Prostacyclin inhibits gastric emptying and small-intestinal transit in rats and dogs.
Ruwart MJ; Rush BD
Gastroenterology; 1984 Aug; 87(2):392-5. PubMed ID: 6376267
[TBL] [Abstract][Full Text] [Related]
13. Antithrombotic effect of TRK-100, a novel, stable PGI2 analogue.
Umetsu T; Murata T; Tanaka Y; Osada E; Nishio S
Jpn J Pharmacol; 1987 Jan; 43(1):81-90. PubMed ID: 3553683
[TBL] [Abstract][Full Text] [Related]
14. Role of H2 receptors in the central and peripheral effects of prostacyclin [PGI2] on circulatory system in rats.
Krzeminski T; Brus R; Juraszczyk Z; Kurcok A; Pogorzelska T
Biomed Biochim Acta; 1984; 43(8-9):S199-202. PubMed ID: 6393966
[TBL] [Abstract][Full Text] [Related]
15. Preservation of platelets and their function in prolonged cardiopulmonary bypass using prostacyclin.
Koshal A; Krausz MM; Utsunomiya T; Hechtman HB; Collins JJ; Cohn LH
Circulation; 1981 Aug; 64(2 Pt 2):II44-8. PubMed ID: 7018736
[TBL] [Abstract][Full Text] [Related]
16. Studies on the behavioral and hypotensive effects of intraventricular prostacyclin (PGI2) in rats.
Brus K; Szkilnik R; Słomińska-Zurek J; Krzemiński T; Herman ZS
Pol J Pharmacol Pharm; 1981 Nov; 33(4):467-74. PubMed ID: 7036117
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological evaluation of 5-(Z,E)-13,14-didehydro-20-methyl-carboprostacyclin (FCE 22509).
Ceserani R; Grossoni M; Ukmar G; Colombo M; Mongelli N
Prostaglandins Leukot Med; 1986 Mar; 21(3):231-45. PubMed ID: 3517883
[TBL] [Abstract][Full Text] [Related]
18. Decreased platelet sensitivity to prostacyclin (epoprostenol) during hemodialysis.
Kristensen SD; Knudsen F; Nielsen AH; Ring T
Clin Nephrol; 1984 Apr; 21(4):230-4. PubMed ID: 6375926
[TBL] [Abstract][Full Text] [Related]
19. Preservation of platelet function and number by prostacyclin during cardiopulmonary bypass.
Coppe D; Sobel M; Seamans L; Levine F; Salzman E
J Thorac Cardiovasc Surg; 1981 Feb; 81(2):274-8. PubMed ID: 7005550
[TBL] [Abstract][Full Text] [Related]
20. [Prostacyclin versus regional heparinisation during haemodialysis (author's transl)].
Hory B; Saunier F; Roy C; Renevier A; Kieffer Y; Saint-Hillier Y; Perol C
Nouv Presse Med; 1982 Jul 10-17; 11(32):2393-7. PubMed ID: 7050907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
